Cuorips proceeded with preparations on the assumption that ReHeart would be listed for reimbursement, and disclosed the first transplant on 29 September. The share price was highly volatile amid related reports from 30 September onward, moving recently from ¥6,640 to ¥6,160 and then to ¥6,580.
ReHeart’s reimbursement listing was scheduled for 1 September, and preparations to begin sales proceeded on that assumption. On 29 September, the company disclosed that the first transplant had been performed, and related reports continued on 30 September.
In its earnings information, the company reported that the next earnings announcement was scheduled for 13 November 2026, and that revenue for the first quarter of the fiscal year ending March 2027 was ¥1.55 million, operating loss was approximately ¥333.42 million, and net loss was approximately ¥317.83 million. Full-scale monetization after reimbursement listing is expected to begin thereafter.
Recent developments include preparations to begin sales after reimbursement listing, establishment of the supply framework, advancement of U.S. development, validation of catheter-based treatment, and expanded research into in-vivo regenerative factors. Risk factors cited include delays in launching ReHeart and the impact of drug price revisions.